ArticleFrontiers in oncology2025
A pelvis MR transformer-based deep learning model for predicting lung metastases risk in patients with rectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Accurate preoperative evaluation of rectal cancer lung metastases (RCLM) is critical for implementing precise medicine. While artificial intelligence (AI) methods have been successful in detecting liver and lymph node metastases using magnetic resonance (MR) images, research on lung metastases is still limited. Utilizing MR images to classify RCLM could potentially reduce ionizing radiation exposure and the costs associated with chest CT in patients without metastases. This study aims to develop and validate a transformer-based deep learning (DL) model based on pelvic MR images, integrated with clinical features, to predict RCLM. Methods: A total of 819 patients with histologically confirmed rectal cancer who underwent preoperative pelvis MRI and carcinoembryonic antigen (CEA) tests were enrolled. Six state-of-the-art DL methods (Resnet18, EfficientNetb0, MobileNet, ShuffleNet, DenseNet, and our transformer-based model) were trained and tested on T2WI and DWI to predict RCLM. The predictive performance was assessed using the receiver operating characteristic (ROC) curve. Results: Our transformer-based DL model achieved impressive results in the independent test set, with an AUC of 83.74% (95% CI, 72.60%-92.83%), a sensitivity of 80.00%, a specificity of 78.79%, and an accuracy of 79.01%. Specifically, for stage T4 and N2 rectal cancer cases, the model achieved AUCs of 96.67% (95% CI, 87.14%-100%, 93.33% sensitivity, 89.04% specificity, 94.74% accuracy), and 96.83% (95% CI, 88.67%-100%, 100% sensitivity, 83.33% specificity, 88.00% accuracy) respectively, in predicting RCLM. Our DL model showed a better predictive performance than other state-of-the-art DL methods. Conclusion: The superior performance demonstrates the potential of our work for predicting RCLM, suggesting its potential assistance in personalized treatment and follow-up plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.